IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
ibrutinib Sensitive: A2 - Guideline
|
ibrutinib Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
obinutuzumab Sensitive: A2 - Guideline
|
obinutuzumab Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
venetoclax + obinutuzumab Sensitive: A2 - Guideline
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
rituximab + idelalisib Sensitive: B - Late Trials
|
rituximab + idelalisib Sensitive: B - Late Trials
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
IGH mutation
|
Small Lymphocytic Lymphoma
|
FCR Sensitive: C3 – Early Trials
|
FCR Sensitive: C3 – Early Trials
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
iFCG Sensitive: C3 – Early Trials
|
iFCG Sensitive: C3 – Early Trials
|